Exelixis (EXEL) PT Lowered to $31 at RBC Capital
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $51.23 -1.31%
Rating Summary:
15 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Rating Summary:
15 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $34.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley on Exelixis (EXEL): today's update 'mixed-to-negative at the margin'
- Alkami Technology Inc (ALKT) PT Lowered to $19 at JPMorgan
- Exelixis colorectal cancer trial misses one of two survival goals
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
